Evidence map›Paper›PMID 34093666›Full record

ArticleFrontiers in genetics2021

DNA Methylation, Deamination, and Translesion Synthesis Combine to Generate Footprint Mutations in Cancer Driver Genes in B-Cell Derived Lymphomas and Other Cancers.

Igor B Rogozin, Abiel Roche-Lima, Kathrin Tyryshkin, Kelvin Carrasquillo-Carrión, Artem G Lada, Lennard Y Poliakov, Elena Schwartz, Andreu Saura, Vyacheslav Yurchenko, David N Cooper and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 6 countries.

Igor B RogozinNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States.
Abiel Roche-LimaCenter for Collaborative Research in Health Disparities - RCMI Program, University of Puerto Rico, San Juan, Puerto Rico.
Kathrin TyryshkinDepartment of Pathology and Molecular Medicine, School of Medicine, Queen's University, Kingston, ON, Canada.
Kelvin Carrasquillo-CarriónIntegrated Informatics Services Core - RCMI, University of Puerto Rico, San Juan, Puerto Rico.
Artem G LadaDepartment Microbiology and Molecular Genetics, University of California, Davis, Davis, CA, United States.
Lennard Y PoliakovLife Science Research Centre, Faculty of Science, University of Ostrava, Ostrava, Czechia.
Elena SchwartzCoordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Andreu SauraLife Science Research Centre, Faculty of Science, University of Ostrava, Ostrava, Czechia.
Vyacheslav YurchenkoLife Science Research Centre, Faculty of Science, University of Ostrava, Ostrava, Czechia.
David N CooperInstitute of Medical Genetics, Cardiff University, Cardiff, United Kingdom.
Anna R PanchenkoDepartment of Pathology and Molecular Medicine, School of Medicine, Queen's University, Kingston, ON, Canada.
Youri I PavlovEppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, United States.
University of Ostrava · CZNational Institutes of Health · USQueen's University · CAUniversity of Puerto Rico System · PRCardiff University · GBSt Petersburg University · RUUniversity of California, Davis · US

Funding

National Biomedical Information ServicesZIHLM200888 · NLM · NATIONAL LIBRARY OF MEDICINE · PI PALTOO, DINA · 2009 to 2025
$5200.7M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Carmen M Velez Vega · 2017 to 2026
$35.8M
NCI NIH HHS P30 CA072720NIMHD NIH HHS U54 MD007600
6 · The paper itself

Abstract

Cancer genomes harbor numerous genomic alterations and many cancers accumulate thousands of nucleotide sequence variations. A prominent fraction of these mutations arises as a consequence of the off-target activity of DNA/RNA editing cytosine deaminases followed by the replication/repair of edited sites by DNA polymerases (pol), as deduced from the analysis of the DNA sequence context of mutations in different tumor tissues. We have used the weight matrix (sequence profile) approach to analyze mutagenesis due to Activation Induced Deaminase (AID) and two error-prone DNA polymerases. Control experiments using shuffled weight matrices and somatic mutations in immunoglobulin genes confirmed the power of this method. Analysis of somatic mutations in various cancers suggested that AID and DNA polymerases η and θ contribute to mutagenesis in contexts that almost universally correlate with the context of mutations in A:T and G:C sites during the affinity maturation of immunoglobulin genes. Previously, we demonstrated that AID contributes to mutagenesis in (de)methylated genomic DNA in various cancers. Our current analysis of methylation data from malignant lymphomas suggests that driver genes are subject to different (de)methylation processes than non-driver genes and, in addition to AID, the activity of pols η and θ contributes to the establishment of methylation-dependent mutation profiles. This may reflect the functional importance of interplay between mutagenesis in cancer and (de)methylation processes in different groups of genes. The resulting changes in CpG methylation levels and chromatin modifications are likely to cause changes in the expression levels of driver genes that may affect cancer initiation and/or progression.

Indexed as

computational biologydatabasefrequency matricesgene expressionimmunoglobulin genessomatic hypermutationtumor cells

Identifiers

PMID34093666
PMCPMC8170131
OpenAlexW3160169558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.